Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT05565378
Title Phase 2 Platform Study of Novel Immunotherapy Combinations in Participants With Previously Untreated, Advanced/Metastatic Non Small Cell Lung Cancer
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors GlaxoSmithKline
Indications

lung non-small cell carcinoma

Therapies

Dostarlimab-gxly

Dostarlimab-gxly + EOS-448

Pembrolizumab

Age Groups: adult | senior
Covered Countries

Additional content available in CKB BOOST